Xcellerex, a Marlborough, Mass. company that makes a manufacturing technology for vaccines and biotherapeutics, said it has raised $11 million more in its second round of funding.

That brings the total second round amount to $20 million.

SCG Group and Kleiner Perkins Caufield and Byers led the round. Kleiner Perkins’ Thomas Monath, M.D., has joined the Xcellerex board of directors.

From the company’s announcement:

Xcellerex is commercializing a highly innovative, modular and scalable manufacturing platform, FlexFactoryâ„¢, which combines single use, disposable components and production-scale disposable stirred tank bioreactor systems (XDRâ„¢). The use of disposable components provides the flexibility to produce multiple products at a common facility, and to establish manufacturing capacity rapidly at dramatically lower costs than traditional fixed tank, hard-piped facilities. Along with its high throughput process development and formulation technologies, Xcellerex provides a fully integrated manufacturing approach with potential across the full range of cell production types. In addition, the portability of the FlexFactory technology enables distributed manufacturing to provide local drug supply capability.

VentureBeat

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
  • up-to-date information on the subjects of interest to you
  • our newsletters
  • gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
  • networking features, and more
Become a member